Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.42 |
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505950 | 0.90 | AHCY (0.39) | ADORA2AADORA2BAHCYHINT1ADORA3 | |
| SCHEMBL6465533 | 0.89 | AHCY (0.38) | ADORA2AADORA2BAHCYHINT1ADORA3 | |
| SCHEMBL4581732 | 0.87 | ADORA3 (0.49) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL27177316 | 0.83 | PNP (0.44) | HINT1ADORA3 | |
| SCHEMBL5506198 | 0.81 | LMNA (0.48) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL6685951 | 0.80 | AHCY (0.46) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL1938201 | 0.80 | AHCY (0.46) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL7919927 | 0.79 | ADORA2A (0.37) | ADORA2AADORA2BAHCYHINT1 | |
| SCHEMBL10709115 | 0.78 | ADORA2A (0.45) | ADORA2AADORA2BHINT1ADORA3ADORA1 | |
| SCHEMBL11012860 | 0.78 | HINT1 (0.39) | ADORA2AADORA2BHINT1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820810-B2 | Process for the synthesis of 2′-O-substituted purine nulceosides | ISIS PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080234475-A1 | PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PURINES | IONIS PHARMACEUTICALS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234475-A1 | PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PURINES | PNP, NUDT1, UMPS | ADORA2A 53/4885ADORA2B 136/4885AHCY 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.